Since cancer cells evade the tumor-suppressive effects of TGF-β and exploit it to maintain motility or malignancy, many human cancers reportedly have genetically inactive mutations in TGF-β receptors or Smads. The gene discussed is TGFB1; the disease is neoplasm.